| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caeeecea8b7564e8576a19d8b6c1e9a7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C319-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-009 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-203 |
| filingDate |
2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33b3706bc48cfcfce15c66be89a7147b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ab19c04a12504230a3ee745df98d28c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8518655c253d3b0ce21c3975f3d251ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efa3d7ca061bbc38221478c6d9d37231 |
| publicationDate |
2019-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019060634-A1 |
| titleOfInvention |
METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS |
| abstract |
The present invention provides methods for treating cystinosis and other cysteamine sensitive disorders in a subject, comprising administering a disulfide convertible to cysteamine in vivo. The methods may include separately administering a reducing agent to the subject to increase the bioavailability and broaden the plasma pharmacokinetic profile of the cysteamine produced following the administration of the disulfide. The methods according to the invention make it possible to obtain sustainable plasma concentrations of cysteamine in the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020127602-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021252373-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11753370-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023129584-A3 |
| priorityDate |
2017-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |